Back to Search Start Over

AZ's Fasenra fails in Phase III COPD study

Source :
M2 Presswire. May 11, 2018
Publication Year :
2018

Abstract

M2 PRESSWIRE-May 11, 2018-: AZ's Fasenra fails in Phase III COPD study (C)1994-2018 M2 COMMUNICATIONS RDATE:11052018 AstraZeneca plc (LSE:AZN; NYSE:AZN) said Fasenra benralizumab failed to significantly reduce exacerbations in patients [...]

Subjects

Subjects :
AstraZeneca PLC -- Product development
Chronic obstructive lung disease -- Care and treatment
Pharmaceutical industry -- Product development
Business
Business, international
Fasenra (Medication)

Details

Language :
English
Database :
Gale General OneFile
Journal :
M2 Presswire
Publication Type :
News
Accession number :
edsgcl.538140487

Tools

Authors Abstract Subjects Details